tetano
Editor, Senior Moderator
J Med Virol
. 2022 Nov 21.
doi: 10.1002/jmv.28326. Online ahead of print.
Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants
Chon Phin Ong[SUP] 1 [/SUP], Zi-Wei Ye[SUP] 1 [/SUP], Kaiming Tang[SUP] 2 [/SUP], Ronghui Liang[SUP] 2 [/SUP], Yubin Xie[SUP] 2 [/SUP], Hongzhuo Zhang[SUP] 1 [/SUP], Zhenzhi Qin[SUP] 2 [/SUP], Haoran Sun[SUP] 3 [/SUP], Tong-Yun Wang[SUP] 2 [/SUP], Yun Cheng[SUP] 1 [/SUP], Hin Chu[SUP] 2 4 3 [/SUP], Jasper Fuk-Woo Chan[SUP] 2 4 3 5 [/SUP], Dong-Yan Jin[SUP] 1 4 5 [/SUP], Shuofeng Yuan[SUP] 2 4 3 [/SUP]
Affiliations
Abstract
The initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, BA.1 and BA.2, are being progressively displaced by BA.5 in many countries. To provide insight on the replacement of BA.2 by BA.5 as the dominant SARS-CoV-2 variant, we performed a comparative analysis of Omicron BA.2.12.1 and BA.5.2 variants in cell culture and hamster models. We found that BA.5.2 exhibited enhanced replicative kinetics over BA.2.12.1 in vitro and in vivo, which is evidenced by the dominant BA.5.2 viral genome detected at different time points, regardless of immune selection pressure with vaccine-induced serum antibodies. Utilising reverse genetics, we constructed a mutant SARS-CoV-2 carrying spike F486V substitution, which is an uncharacterized mutation that concurrently discriminates Omicron BA.5.2 from BA.2.12.1 variant. We noticed that the 486[SUP]th[/SUP] residue does not confer viral replication advantage to the virus. We also found that 486V displayed generally reduced immune evasion capacity when compared with its predecessor, 486F. However, the surge of fitness in BA.5.2 over BA.2.12.1 was not due to stand-alone F486V substitution but as a result of combination of multiple mutations. Our study upholds the urgency for continuous monitoring of SARS-CoV-2 Omicron variants with enhanced replication fitness. This article is protected by copyright. All rights reserved.
Keywords: BA.2.12.1; BA.5.2; F486V; Neutralising antibodies; Reverse genetics.
. 2022 Nov 21.
doi: 10.1002/jmv.28326. Online ahead of print.
Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants
Chon Phin Ong[SUP] 1 [/SUP], Zi-Wei Ye[SUP] 1 [/SUP], Kaiming Tang[SUP] 2 [/SUP], Ronghui Liang[SUP] 2 [/SUP], Yubin Xie[SUP] 2 [/SUP], Hongzhuo Zhang[SUP] 1 [/SUP], Zhenzhi Qin[SUP] 2 [/SUP], Haoran Sun[SUP] 3 [/SUP], Tong-Yun Wang[SUP] 2 [/SUP], Yun Cheng[SUP] 1 [/SUP], Hin Chu[SUP] 2 4 3 [/SUP], Jasper Fuk-Woo Chan[SUP] 2 4 3 5 [/SUP], Dong-Yan Jin[SUP] 1 4 5 [/SUP], Shuofeng Yuan[SUP] 2 4 3 [/SUP]
Affiliations
- PMID: 36411262
- DOI: 10.1002/jmv.28326
Abstract
The initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, BA.1 and BA.2, are being progressively displaced by BA.5 in many countries. To provide insight on the replacement of BA.2 by BA.5 as the dominant SARS-CoV-2 variant, we performed a comparative analysis of Omicron BA.2.12.1 and BA.5.2 variants in cell culture and hamster models. We found that BA.5.2 exhibited enhanced replicative kinetics over BA.2.12.1 in vitro and in vivo, which is evidenced by the dominant BA.5.2 viral genome detected at different time points, regardless of immune selection pressure with vaccine-induced serum antibodies. Utilising reverse genetics, we constructed a mutant SARS-CoV-2 carrying spike F486V substitution, which is an uncharacterized mutation that concurrently discriminates Omicron BA.5.2 from BA.2.12.1 variant. We noticed that the 486[SUP]th[/SUP] residue does not confer viral replication advantage to the virus. We also found that 486V displayed generally reduced immune evasion capacity when compared with its predecessor, 486F. However, the surge of fitness in BA.5.2 over BA.2.12.1 was not due to stand-alone F486V substitution but as a result of combination of multiple mutations. Our study upholds the urgency for continuous monitoring of SARS-CoV-2 Omicron variants with enhanced replication fitness. This article is protected by copyright. All rights reserved.
Keywords: BA.2.12.1; BA.5.2; F486V; Neutralising antibodies; Reverse genetics.